chenodeoxycholic acid has been researched along with Diabetes Mellitus, Type 2 in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Costantino, G; Fiorucci, S; Pellicciari, R | 1 |
| Huang, TL; Mayence, A; Vanden Eynde, JJ | 1 |
| Balic, K; Grimsby, J; Huang, Y; Konkar, A; Liang, L; Naylor, J; Patel, C; Pechenov, S; Revell, J; Rosenbaum, AI; Subramony, JA; Tseng, L; Tyagi, P; Will, S | 1 |
| Cao, Y; Huang, L; Jin, E; Li, S; Qu, J; Ren, C; Tang, J; Wang, J; Wang, Z; Zhang, L; Zhao, M; Zhong, Y; Zhou, W | 1 |
| Chen, C; Cheng, ZQ; Dai, Y; Liu, TM; Ren, PF; Wang, YL; Zhang, X | 1 |
| Adams-Haduch, J; Boffetta, P; Bui, NC; Clemente, JC; Ha, HT; Jia, W; Le, LC; Luu, HN; Nguyen, MV; Pham, HT; Schoen, RE; Thomas, CE; Tran, CT; Tran, MT; Tran, QH; Trinh, DT; Tuong, TT; Velikokhatnaya, L; Vu, HH; Wang, R; Xie, G; Yuan, JM | 1 |
| Chen, S; Fang, L; Fang, Q; Jia, W; Li, H; Song, Q; Xu, A; Xu, J; Yan, H; Ye, Y; Zhang, J; Zhang, Y; Zhou, H | 1 |
| Adinolfi, LE; Lonardo, A; Marrazzo, A; Maurantonio, M; Nascimbeni, F; Rinaldi, L | 1 |
| Adorini, L; D'Agati, V; Dobrinskikh, E; Dvornikov, A; Field, A; Garcia, G; Gonzalez, FJ; Gratton, E; Henriksen, K; Herman-Edelstein, M; Hill, A; Jiang, T; Kopp, JB; Krausz, KW; Levi, J; Levi, M; Lucia, S; Luo, Y; Myakala, K; Orlicky, D; Peng, Y; Pruzanski, M; Qiu, L; Ranjit, S; Rosenberg, AZ; Wang, D; Wang, XX; Xie, C | 1 |
| Adorini, L; Castelloe, E; Clopton, P; Dillon, P; Henry, RR; Kipnes, M; Marschall, HU; Morrow, L; Mudaliar, S; Pruzanski, M; Sanyal, AJ; Sciacca, CI; Shapiro, D | 1 |
| Karpen, SJ | 1 |
| Al-Salami, H; Arfuso, F; Golocorbin-Kon, S; Mikov, M; Mooranian, A; Negrulj, R | 1 |
| Bao, Y; Chen, T; Jia, W; Ni, Y; Su, M; Tu, Y; Wei, L; Xie, G; Yu, H; Zhang, L; Zhang, P; Zhao, A | 1 |
| Chen, D; Chen, W; Liu, HL; Wang, X; Wu, ZH; Zeng, TS; Zhang, HM; Zhang, ZZ | 1 |
| Hansen, JS; Hansen, M; Holst, JJ; Knop, FK; Rehfeld, JF; Scheltema, MJ; Sonne, DP; Sperling, M; Vilsbøll, T | 1 |
| Cahen, DL; Diamant, M; Groen, AK; Hoekstra, T; Kramer, MH; Muskiet, MH; Nieuwdorp, M; Smits, MM; Tonneijck, L; van Raalte, DH | 1 |
| Bloks, VW; Brufau, G; Burgerhof, HG; Kuipers, F; Murphy, EJ; Romijn, HA; Scheltema, RA; Smelt, GH; Stellaard, F | 1 |
| Nozawa, H | 1 |
3 review(s) available for chenodeoxycholic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Farnesoid X receptor: from structure to potential clinical applications.
Topics: Animals; Bile Acids and Salts; Binding Sites; Cardiovascular Diseases; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Insulin Resistance; Ligands; Models, Molecular; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2005 |
Some non-conventional biomolecular targets for diamidines. A short survey.
Topics: Amidines; Animals; Diabetes Mellitus, Type 2; DNA; Enzymes; Humans; Hypertension; Ion Channels; Myotonic Dystrophy; Neoplasms; Neurodegenerative Diseases; Proteins; RNA; Thrombosis | 2014 |
Nonalcoholic fatty liver disease: Evolving paradigms.
Topics: Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Diagnostic Imaging; Diet, Reducing; Dyslipidemias; Exercise Therapy; Humans; Hyperuricemia; Hypoglycemic Agents; Liver; Liver Function Tests; Liver Neoplasms; Mass Screening; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Assessment; Risk Factors; Vitamin E | 2017 |
3 trial(s) available for chenodeoxycholic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Topics: Adult; Aged; Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2013 |
Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
Topics: Aged; Bile Acids and Salts; Blood Glucose; C-Peptide; Chenodeoxycholic Acid; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Placebos | 2016 |
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Topics: Aged; Bile Acids and Salts; Blood Glucose; Chenodeoxycholic Acid; Cholic Acid; Deoxycholic Acid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Feces; Female; Gallbladder; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Organ Size; Postprandial Period; Sitagliptin Phosphate; Sulfonylurea Compounds; Ultrasonography; Ursodeoxycholic Acid | 2016 |
12 other study(ies) available for chenodeoxycholic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.
Topics: Administration, Oral; Animals; Caco-2 Cells; Chemistry, Pharmaceutical; Chenodeoxycholic Acid; CHO Cells; Chronic Disease; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Drug Delivery Systems; Drug Discovery; Glucagon-Like Peptide-1 Receptor; Humans; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Peptides; Propyl Gallate; Protein Engineering; Receptors, Glucagon; Tablets, Enteric-Coated | 2021 |
Metabolomic comparison followed by cross-validation of enzyme-linked immunosorbent assay to reveal potential biomarkers of diabetic retinopathy in Chinese with type 2 diabetes.
Topics: Aged; Biomarkers; Carnitine; Case-Control Studies; Chenodeoxycholic Acid; China; Citrulline; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Humans; Metabolomics; Phosphatidylcholines | 2022 |
Duodenal-jejunal bypass reduces serum ceramides
Topics: Animals; Bile Acids and Salts; Blood Glucose; Ceramides; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Duodenum; Glucose; Jejunum; Rats; Salicylamides; Streptozocin | 2022 |
Associations between Ileal Juice Bile Acids and Colorectal Advanced Adenoma.
Topics: Adenoma; Bile Acids and Salts; Chenodeoxycholic Acid; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Ursodeoxycholic Acid | 2023 |
Lowered fasting chenodeoxycholic acid correlated with the decrease of fibroblast growth factor 19 in Chinese subjects with impaired fasting glucose.
Topics: Blood Glucose; Body Mass Index; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Fasting; Female; Fibroblast Growth Factors; Glucose; Glucose Tolerance Test; Hep G2 Cells; Humans; Insulin; Intestinal Mucosa; Male | 2017 |
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
Topics: Albuminuria; Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholesterol; Cholic Acids; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Endoplasmic Reticulum Stress; Fibrosis; Glomerular Mesangium; Humans; Kidney Tubules; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mitochondria; Obesity; Oxidative Stress; Podocytes; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction; Triglycerides | 2018 |
Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD?
Topics: Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2013 |
Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study.
Topics: Administration, Oral; Alginates; Bile Acids and Salts; Calorimetry, Differential Scanning; Capsules; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Drug Compounding; Drug Delivery Systems; Drug Stability; Glucuronic Acid; Hexuronic Acids; Humans; Hydrogen-Ion Concentration; Microscopy, Electron, Scanning; Particle Size; Powders; Probucol; Rheology; Spectroscopy, Fourier Transform Infrared; Surface Properties; Temperature; Viscosity; X-Ray Microtomography | 2015 |
Chenodeoxycholic Acid as a Potential Prognostic Marker for Roux-en-Y Gastric Bypass in Chinese Obese Patients.
Topics: Adult; Anastomosis, Roux-en-Y; Asian People; Bile Acids and Salts; Biomarkers; Body Mass Index; Chenodeoxycholic Acid; China; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Obesity; Overweight; Predictive Value of Tests; Prognosis; Retrospective Studies; Treatment Outcome | 2015 |
Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model.
Topics: Animals; Body Weight; Chenodeoxycholic Acid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Gluconeogenesis; Glucose-6-Phosphatase; Liver; Male; Phosphoenolpyruvate Carboxykinase (ATP); Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors | 2016 |
Two time-point assessment of bile acid kinetics in humans using stable isotopes.
Topics: Bile Acids and Salts; Carbon Isotopes; Chenodeoxycholic Acid; Cholic Acid; Deoxycholic Acid; Deuterium; Diabetes Mellitus, Type 2; Female; Humans; Hypertriglyceridemia; Isotope Labeling; Kinetics; Male; Obesity; Radioisotope Dilution Technique; Reference Values; Time Factors | 2010 |
Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Cell Line, Tumor; Chalcones; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Flavonoids; Gene Expression; Glucose; Humans; Humulus; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Ligands; Lipid Metabolism; Liver; Male; Mice; Mice, Obese; Propiophenones; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides | 2005 |